Previous 10 | Next 10 |
Nano-cap pharma Altamira Therapeutics ( NASDAQ: CYTO ) lost ~6% pre-market Friday after announcing plans to increase its authorized share capital to meet future funding needs and accommodate changes to a financing facility. The decision comes after FiveT Investment Management agreed t...
HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Process for divestiture / partnering of legacy assets continues Strong data from Bentrio ® NASAR study reinforces its therapeutic benefit for allergic rhinitis Case for Bentrio’s protective effect in vira...
Altamira Therapeutics ( NASDAQ: CYTO ) is trading 26% down after the company said its therapy, Bentrio, to treat acute COVID-19, did not meet main goal in a trial. Top line data from the trial, dubbed Covamid, showed trend for more pronounced reduction in nasal viral...
HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal spray comparator NASAR main trial phase...
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhore TM platform’s functionality with mRNA, and: Peptide-based platform for extrahepatic delivery The extrahepatic success of, and prospects for, SemaPhore vs ...
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Provides Year - End 2022 Business Update Strategic Bentrio TM partnering or divestiture process enters decisive phase Partnering or divestiture process for inner ear therapeutics a...
Altamira Therapeutics ( NASDAQ: CYTO ) on Tuesday announced peer-reviewed publication of data that showed that its RNA delivery platform was an effective treatment for abdominal aortic aneurysm (AAA) in rodents. The peer-reviewed article was titled "Peptide-siRNA nanop...
Study results appeared in "Biomaterials Advances", a highly respected peer-reviewed journal, showcasing growing medical recognition of Company's patented RNA delivery platform for extrahepatic targets. Company's RNA delivery platform demonstrated effectiveness in mitigating abdominal a...
Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses HAMILTON, BERMUDA / ACCESSWIRE / June 29, 2022 / Altamira Therapeutics Ltd. ("the Company") (NASDAQ:CYTO ), a company ded...
Shares of Altamira Therapeutics (CYTO) are up 27% in premarket trading after the U.S. FDA granted 510(k) clearance to market nasal spray Bentrio for allergic rhinitis. Bentrio is a drug-free products that forms a thin layer on the n nasal mucosa to prevent allergens from coming on c...
News, Short Squeeze, Breakout and More Instantly...
Altamira Therapeutics Ltd. Company Name:
CYTO Stock Symbol:
NASDAQ Market:
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or t...
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated ...
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDT RNA delivery business progressing with new collaborations, potential new applications Partnering of legacy assets underway as Company transitions to f...